Umbelliferone Prevents Lipopolysaccharide-Induced Bone Loss and Suppresses RANKL-Induced Osteoclastogenesis by Attenuating Akt-c-Fos-NFATc1 Signaling
Open Access
- 1 January 2019
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 15 (11) , 2427-2437
Abstract
Excessive bone resorption plays a central role in the development of inflammatory bone diseases, including osteoporosis and rheumatoid arthritis. Thus, identification of agents that can effectively suppress excessive osteoclast formation and function is crucial for the prevention and treatment of inflammatory bone loss. Umbelliferone (Umb), a derivative of coumarin, is a natural bioactive compound with anti-inflammatory and antioxidant properties. However, the effect of Umb on metabolic bone diseases is unknown. In this study, we found that Umb exhibited a strong inhibitory effect on lipopolysaccharide (LPS)-induced inflammatory bone loss in vivo. Histological analysis confirmed that Umb prevented trabecular bone matrix degradation and osteoclast formation in bone tissue. In addition, Umb suppressed RANKL-induced osteoclast differentiation and abrogated bone resorption. We found that the anti-osteoclastic and anti-resorptive activities of Umb are mediated via suppression of the RANKL-induced Akt-c-Fos-NFATc1 signaling pathway and the attenuation of osteoclast-specific genes, such as TRAP, OSCAR, ATP6v0d2, and CtsK. In particular, Umb downregulated the stability of c-Fos and NFATc1 proteins, but did not suppress the expression of their mRNAs. These results indicate that Umb may be a potential therapeutic agent for inflammatory bone diseases associated with abnormal osteoclast formation and function.Keywords
This publication has 28 references indexed in Scilit:
- LPS Promotes Pre-osteoclast Activity by Up-regulating CXCR4 via TLR-4Journal of Dental Research, 2011
- Antinociceptive and anti-inflammatory properties of 7-hydroxycoumarin in experimental animal models: potential therapeutic for the control of inflammatory chronic painJournal of Pharmacy and Pharmacology, 2010
- Osteoporosis in Inflammatory Bowel DiseaseThe American Journal of Medicine, 2009
- Myocyte Enhancer Factor 2 and Microphthalmia-associated Transcription Factor Cooperate with NFATc1 to Transactivate the V-ATPase d2 Promoter during RANKL-induced OsteoclastogenesisJournal of Biological Chemistry, 2009
- Lipopolysaccharides (LPS) induce the differentiation of human monocytes to osteoclasts in a tumour necrosis factor (TNF) α-dependent manner: A link between infection and pathological bone resorptionMolecular Immunology, 2008
- Osteoporosis and InflammationNutrition Reviews, 2008
- Akt1 in Osteoblasts and Osteoclasts Controls Bone RemodelingPLOS ONE, 2007
- Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2Genes & Development, 2003
- Osteoclast differentiation and activationNature, 2003
- Adherent Endotoxin on Orthopedic Wear Particles Stimulates Cytokine Production and Osteoclast DifferentiationJournal of Bone and Mineral Research, 2001